479 related articles for article (PubMed ID: 26583156)
1. Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines.
Goyvaerts C; Breckpot K
J Immunol Res; 2015; 2015():785634. PubMed ID: 26583156
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cells for specific cancer immunotherapy.
Meidenbauer N; Andreesen R; Mackensen A
Biol Chem; 2001 Apr; 382(4):507-20. PubMed ID: 11405216
[TBL] [Abstract][Full Text] [Related]
3. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Reardon DA; Mitchell DA
Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
[TBL] [Abstract][Full Text] [Related]
4. Current status and future perspectives of dendritic cell-based cancer immunotherapy.
H Yi D; Appel S
Scand J Immunol; 2013 Aug; 78(2):167-71. PubMed ID: 23672402
[TBL] [Abstract][Full Text] [Related]
5. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cell-based nanovaccines for cancer immunotherapy.
Paulis LE; Mandal S; Kreutz M; Figdor CG
Curr Opin Immunol; 2013 Jun; 25(3):389-95. PubMed ID: 23571027
[TBL] [Abstract][Full Text] [Related]
7. Enhancing efficacy of anticancer vaccines by targeted delivery to tumor-draining lymph nodes.
Jeanbart L; Ballester M; de Titta A; Corthésy P; Romero P; Hubbell JA; Swartz MA
Cancer Immunol Res; 2014 May; 2(5):436-47. PubMed ID: 24795356
[TBL] [Abstract][Full Text] [Related]
8. The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.
Salem ML
Methods Mol Biol; 2014; 1139():479-503. PubMed ID: 24619701
[TBL] [Abstract][Full Text] [Related]
9. Coupled for cross-presentation in tumor immunotherapy.
Pang B; Neefjes J
Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
[TBL] [Abstract][Full Text] [Related]
10. Dendritic Cell-Based Cancer Vaccines.
Santos PM; Butterfield LH
J Immunol; 2018 Jan; 200(2):443-449. PubMed ID: 29311386
[TBL] [Abstract][Full Text] [Related]
11. mRNA-based dendritic cell vaccines.
Benteyn D; Heirman C; Bonehill A; Thielemans K; Breckpot K
Expert Rev Vaccines; 2015 Feb; 14(2):161-76. PubMed ID: 25196947
[TBL] [Abstract][Full Text] [Related]
12. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
13. Advances in dendritic cell-based vaccine of cancer.
Zhang X; Gordon JR; Xiang J
Cancer Biother Radiopharm; 2002 Dec; 17(6):601-19. PubMed ID: 12537664
[TBL] [Abstract][Full Text] [Related]
14. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy.
Aikins ME; Xu C; Moon JJ
Acc Chem Res; 2020 Oct; 53(10):2094-2105. PubMed ID: 33017150
[TBL] [Abstract][Full Text] [Related]
15. DNA vaccine for cancer immunotherapy.
Yang B; Jeang J; Yang A; Wu TC; Hung CF
Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927
[TBL] [Abstract][Full Text] [Related]
16. A review of dendritic cell therapy for cancer: progress and challenges.
Mantia-Smaldone GM; Chu CS
BioDrugs; 2013 Oct; 27(5):453-68. PubMed ID: 23592406
[TBL] [Abstract][Full Text] [Related]
17. The ReNAissanCe of mRNA-based cancer therapy.
Van Lint S; Renmans D; Broos K; Dewitte H; Lentacker I; Heirman C; Breckpot K; Thielemans K
Expert Rev Vaccines; 2015 Feb; 14(2):235-51. PubMed ID: 25263094
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cell preparation for immunotherapeutic interventions.
Simon T; Fonteneau JF; Grégoire M
Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
[TBL] [Abstract][Full Text] [Related]
19. [Immunology in medical practice. XXV. Use of dendritic cells in the immunotherapy of cancer].
Punt CJ; de Vries IJ; Mulders PF; Adema GJ; Figdor CG
Ned Tijdschr Geneeskd; 1999 Nov; 143(48):2408-14. PubMed ID: 10608974
[TBL] [Abstract][Full Text] [Related]
20. Cancer vaccines. Any future?
Myc LA; Gamian A; Myc A
Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
